Novavax Might Supply 100M Covid-19 Injection Doses By End of Year, Claims R.

May.14 — Novavax Inc.’s vaccine is one of at least 100 potential candidates trying to curb the spread of the virus that causes Covid-19. The biotech company recently received a funding of $388-million from the Coalition for Epidemic Preparedness Innovation, making it the biggest investment ever from the group. Dr. Gregory Glenn, Novavax’s president of research and development, speaks on “Bloomberg Technology.”

Leave a Reply

Your email address will not be published. Required fields are marked *